



**Ruth E. Gimeno, Ph.D., Group Vice President, Diabetes, Obesity & Cardiometabolic Research and Early Clinical Development, Eli Lilly and Company**

Named in 2022 as one of the top 20 women leading biopharma R&D by *Endpoints News*, Dr. Gimeno joined Lilly in 2011 and leads research and early clinical development in diabetes, obesity and cardiometabolic disorders. Under her leadership, Lilly has built a strong early-phase clinical pipeline in these areas and has advanced several innovative molecules into Phase 3 and to the market, including Basal Insulin Fc (BIF), a novel weekly basal insulin (in phase 3); Lyumjev®, an ultrarapid insulin lispro formulation; and tirzepatide, a first-in-class dual GIP and GLP-1 receptor agonist (approved for type 2 diabetes and marketed as Mounjaro®; currently in Phase 3 clinical studies for obesity, cardiovascular disease, obstructive sleep apnea, and heart failure).

Dr. Gimeno is also helping to lead Lilly's efforts to develop genetic medicines targeting diabetes, cardiovascular disease, obesity, and other metabolic disorders.

Dr. Gimeno received undergraduate training in medicine at the Julius-Maximilians-University in Würzburg, Germany, and obtained a Ph.D. in biology from the Massachusetts Institute of Technology in Cambridge, USA.

Prior to joining Lilly in 2011, Dr. Gimeno led research teams focused on metabolic disease drug discovery at Millennium Pharmaceuticals, Wyeth and Pfizer.

###